Charles Kerr, DO
Family Medicine · Bay City, MINPI 1568495406
Payments from drug & device makers
Across 204 payments — averaging $17.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$499
- AstraZeneca$465
- Boehringer Ingelheim$384
- Novo Nordisk$374
- Merck$272
- AbbVie$212
- plus $1K from 23 others
What the payments were for
- Food & beverage$3,48197%
- Education$1253%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 32 | $499 |
| AstraZeneca | 25 | $465 |
| Boehringer Ingelheim | 16 | $384 |
| Novo Nordisk | 22 | $374 |
| Merck | 18 | $272 |
| AbbVie | 10 | $212 |
| Bayer | 8 | $153 |
| Astellas Pharma US Inc | 6 | $130 |
| Amgen | 7 | $118 |
| Novartis | 8 | $114 |
| Exact Sciences | 5 | $108 |
| Johnson & Johnson | 6 | $105 |
| GSK | 7 | $103 |
| Pfizer | 6 | $99 |
| Otsuka America Pharmaceutical, Inc. | 5 | $92 |
| Sumitomo Pharma America, Inc. | 3 | $52 |
| Teva Pharmaceuticals USA, Inc. | 4 | $51 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $46 |
| Abbott | 2 | $40 |
| Viatris Specialty LLC | 2 | $33 |
| E.r. Squibb & Sons, L.L.C. | 2 | $28 |
| Mylan Specialty L.p. | 1 | $25 |
| Hikma Pharmaceuticals USA | 1 | $21 |
| Phathom Pharmaceuticals, Inc. | 1 | $18 |
| Aimmune Therapeutics, Inc. | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $12 |
| Avanir Pharmaceuticals, Inc. | 1 | $11 |
How this compares
$3,606 in reported general payments places this provider in the 85th percentile of 3,945 family medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 220 | $294,551 |
| JardianceEmpagliflozin | 228 | $288,586 |
| MounjaroTirzepatide | 193 | $247,727 |
| TrulicityDulaglutide | 110 | $196,252 |
| FarxigaDapagliflozin Propanediol | 110 | $137,618 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 127 | $133,667 |
| OzempicSemaglutide | 66 | $101,557 |
| XareltoRivaroxaban | 53 | $79,237 |
| Dupixent PenDupilumab | 11 | $40,307 |
| TradjentaLinagliptin | 43 | $39,148 |
| KerendiaFinerenone | 20 | $35,019 |
| RybelsusSemaglutide | 21 | $34,899 |
| MyrbetriqMirabegron | 39 | $33,479 |
| EntrestoSacubitril/Valsartan | 25 | $31,904 |
| RexultiBrexpiprazole | 20 | $27,178 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $499 | $443,979303 claims |
| Boehringer IngelheimJardiance, Tradjenta | $384 | $327,734271 claims |
| PfizerEliquis, Paxlovid | $99 | $302,997235 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta, Symbicort | $465 | $175,552148 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $103 | $144,036145 claims |
| Novo NordiskOzempic, Rybelsus | $374 | $136,45787 claims |
| Johnson & JohnsonXarelto | $105 | $79,23753 claims |
| BayerKerendia | $153 | $35,01920 claims |
| Astellas Pharma US IncMyrbetriq | $130 | $33,47939 claims |
| NovartisEntresto | $114 | $31,90425 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $92 | $27,17820 claims |
| MerckJanuvia | $272 | $18,94619 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,945 family medicine providers in Michigan.
Other family medicine in Bay City
- James CampauBay City$32K
- Derrick WilliamsonSouthfield$9.9M
- Rebecca RivardRoseville$7M
- Paul BensonBerkley$4.2M
- Michael HafranEast Lansing$2.7M
- Mitzie HewittBuckley$1.3M
- Loren ChudlerSouthfield$1.3M
- Solomon AmsterWhite Lake$981K
- Matt RosenbergJackson$559K
- Rhonda MejeurGrand Rapids$493K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.